{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["mocertatug rezetecan"]],"indication":"endometrial cancer after platinum-based chemotherapy and immunotherapy","name":"BEHOLD-Endometrial01","nct_id":"NCT07286331","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=behold-endometrial01-nct07286331. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive Mocertatug rezetecan","label":"Mocertatug rezetecan","type":"EXPERIMENTAL"},{"description":"Participants will receive standard of care treatment (Paclitaxel or Doxorubicin) as per investigator's discretion","label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":["ENGOT, GOG, APGOT"],"completion_date":{"date":"2029-05-30","type":"ESTIMATED"},"conditions":["Neoplasms, Endometrial"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Mocertatug rezetecan","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"GlaxoSmithKline","official_title":"A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-02-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate (ORR) by BICR","timeFrame":"Up to approximately 97 weeks"},{"measure":"Progression Free Survival (PFS) by BICR","timeFrame":"Up to approximately 97 weeks"}],"references":[],"start_date":{"date":"2026-06-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","url":"https://clinicaltrials.gov/study/NCT07286331"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/behold-endometrial01-nct07286331"}